Clinical trials: Hyperlipoproteinemia (a)
Hyperlipidemia, Ursodeoxycholic Acid
Ursodeoxycholic Acid Attenuates Statin-Induced Impaired Glucose Tolerance
The purpose of this clinical trial is to understand whether the drug Ursodeoxycholic acid (UDCA) can prevent glucose intolerance in participants with hyperlipidemia who are taking statins. It will also assess the safety of UDCA.
- Conditions
- Hyperlipidemia, Ursodeoxycholic Acid, Statin Therapy, Glucose Intolerance
- Trial name
- URSTAR (NCT06684106)
- Testing
- Ursodeoxycholic acid (UDCA) 500 mg
- Where
- 2 sites in China
- Volunteers
- 128 people, healthy volunteers welcome
- Sponsor
- First Affiliated Hospital Xi'an Jiaotong University
Nonalcoholic Fatty Liver Disease, Dyslipidemias
Phase IV Study to Evaluate the Effects of Statin Monotherapy or Statin / Ezetimibe Combination Therapy on Hepatic Steatosis in Patients With Hyperlipidemia and Nonalcoholic Fatty Liver Disease
To investigate the therapeutic effect of ezetimibe on nonalcoholic fatty liver disease, the effect of rosuvastatin 5mg monotherapy and rosuvastatin 5mg / ezetimibe 10mg combination therapy n patients with hyperlipidemia and fatty…
- Trial name
- NCT03434613
- Testing
- Rosuvastatin, Rosuvastatin/ezetimibe combination
- Where
- South Korea
- Volunteers
- 64 people
- Sponsor
- Yonsei University
Hypercholesterolemia, Hyperlipoproteinemia
A Study Comparing the Mechanisms of Action of Lifibrol and Pravastatin
Lifibrol is a new lipid-lowering drug which lowers cholesterol to an extent in the order of magnitude of the statins. The mechanism of action of this compound is different from the one of statins but remains unknown.
- Trial name
- NCT01057654
- Testing
- Pravastatin, Lifibrol
- Where
- Germany
- Volunteers
- 18 people, healthy volunteers welcome
- Sponsor
- University Hospital, Bonn
Lipoprotein Disorder
A Study of LY3473329 in Adult Participants With Elevated Lipoprotein(a) at High Risk for Cardiovascular Events
The main purpose of this study is to evaluate the efficacy and safety of LY3473329 in adult participants with elevated Lp(a) at high risk for cardiovascular events.
- Trial name
- KRAKEN (NCT05563246)
- Testing
- LY3473329
- Where
- 42 sites in United States, Australia and 6 more
- Volunteers
- 233 people
- Sponsor
- Eli Lilly and Company
Hyperlipidemia, Type 2 Diabetes
A Single Center Study to Evaluate the Efficacy and Safety of ETC 1002 in Subjects With Type 2 Diabetes
This Phase 2 study will asses the LDL-C lowering efficacy of ETC-1002 versus placebo in subjects with type 2 diabetes.
- Trial name
- NCT01607294
- Testing
- ETC-1002
- Where
- United States
- Volunteers
- 60 people
- Sponsor
- Esperion Therapeutics, Inc.
Lipid Metabolism, Inborn Errors, Hypercholesterolemia, Autosomal Dominant
Study to Assess the Safety and Efficacy of ISIS 301012 (Mipomersen) in Homozygous Familial Hypercholesterolemia
The purpose of this study is to evaluate the safety and efficacy of mipomersen (ISIS 301012) in subjects with homozygous familial hypercholesterolemia on lipid-lowering therapy.
- Conditions
- Lipid Metabolism, Inborn Errors, Hypercholesterolemia, Autosomal Dominant, Hyperlipidemias, Metabolic Diseases
- Trial name
- RADICHOL 1 (NCT00607373)
- Testing
- mipomersen
- Where
- 10 sites in United States, Brazil and 5 more
- Volunteers
- 51 people
- Sponsor
- Kastle Therapeutics, LLC
Homozygous Familial Hypercholesterolemia
Safety and Effectiveness of Evinacumab for the Treatment of Homozygous Familial Hypercholesterolemia
This is an open-label study designed to evaluate the long-term safety and efficacy of evinacumab, a fully human ANGPTL3 antibody, in patients with homozygous familial hypercholesterolemia (HoFH), in a real-life setting in Canada.
- Trial name
- NCT05611528
- Testing
- Evinacumab
- Where
- Canada
- Volunteers
- 10 people
- Sponsor
- Daniel Gaudet
Healthy Volunteers With Hyperlipidemia
A First In Human (FIH) Study to Learn if Different Doses of ALN-ANG3 Are Safe and Well Tolerated in Healthy Adults
This study is researching an experimental drug called ALN-ANG3 (called "study drug"). The study is focused on healthy participants with an elevated level of blood lipids (eg, cholesterol and triglycerides).
- Trial name
- NCT06452771
- Testing
- ALN-ANG3
- Where
- New Zealand
- Volunteers
- 59 people, healthy volunteers welcome
- Sponsor
- Regeneron Pharmaceuticals
Hyperlipemia
The Safety and Efficacy of Multiple-dose of JS002 in Subject With Hyperlipidemia
JS002 is a recombinant humanized anti-PCSK9 monoclonal antibody. This is a randomized, double-blind, placebo-controlled study to evaluate the safety and efficacy, as well as immunogenicity of JS002 treated repeatedly in patients…
- Trial name
- NCT04781114
- Testing
- JS002
- Where
- 57 sites in China
- Volunteers
- 806 people
- Sponsor
- Shanghai Junshi Bioscience Co., Ltd.
Myalgia, Hypercholesterolemia
Study of the Safety and Tolerability Associated With PPD10558 Versus Atorvastatin in Patients Previously Intolerant to Statins Due to Statin-associated Myalgia (SAM)
The purpose of this study is to assess the incidence of statin-associated myalgia (SAM) with treatment with PPD10558 versus atorvastatin in patients previously intolerant to statins.
- Conditions
- Myalgia, Hypercholesterolemia, Hyperlipidemia
- Trial name
- NCT01279590
- Testing
- PPD10558, Atorvastatin
- Where
- 67 sites in United States
- Volunteers
- 282 people
- Sponsor
- Furiex Pharmaceuticals, Inc
Hypertriglyceridemia, Mixed Hyperlipidemia
A Pilot Study to Evaluate the Lipid Effects of TRIA-662
The purpose of this pilot study is to learn what study factors are important in designing a large, full-scale study of the effects of TRIA-662 on serum triglycerides (TG) and high-density lipoprotein cholesterol (HDL-C) levels.
- Trial name
- NCT02008084
- Testing
- TRIA-662
- Where
- 17 sites in Canada
- Volunteers
- 71 people
- Sponsor
- Cortria Corporation
Homozygous Familial Hypercholesterolemia
Evaluate the Efficacy and Safety of SHR-1918 in Patients With Homozygous Familial Hypercholesterolemia
This is a single-arm, open-label study to assess the reduction of low-density lipoprotein cholesterol (LDL-C) by SHR-1918 in patients with homozygous familial hypercholesterolemia (HoFH).
- Trial name
- NCT06009393
- Testing
- SHR-1918
- Where
- China
- Volunteers
- 26 people
- Sponsor
- Beijing Suncadia Pharmaceuticals Co., Ltd
Primary Hyperlipidemia
A Clinical Study to Evaluate the Efficacy and Safety of Bempedoic Acid
This trial is a multicenter randomized, double-blind, placebo-controlled phase III study to evaluate the efficacy and safety of Bempedoic Acid Tablets in patients with hyperlipidemia not adequately controlled by Statins.
- Trial name
- NCT07623915
- Testing
- Bempedoic Acid Tablet
- Volunteers
- 222 people
- Sponsor
- CSPC Ouyi Pharmaceutical Co., Ltd.
ACS (Acute Coronary Syndrome), Hyperlipidemia
Electronic Health Record Augmented LDL-Cholesterol Optimization and Control Via Active Lipid Engagement (EHR-LOCALE): A Quality Improvement Implementation Study
The purpose of this study is to determine whether a proactive, EHR-guided approach helps more individuals reach safe cholesterol levels, improves medication use, and reduces future heart attacks and strokes, compared to usual…
- Conditions
- ACS (Acute Coronary Syndrome), Hyperlipidemia, Dyslipidemia, Low-Density-Lipoprotein-cholesterol Level
- Trial name
- EHR-LOCALE (NCT07685639)
- Testing
- Pharmacist-led lipid optimization pathway
- Where
- 2 sites in Canada
- Volunteers
- 2,000 people
- Sponsor
- University of Alberta
Rheumatoid Arthritis, Cardiovascular Diseases
Cardiovascular Risk Assessment for Patients With Rheumatoid Arthritis Arthritis:
One of the greatest success stories in rheumatology - the achievement of rheumatoid arthritis (RA) remission - is tempered by the fact that individuals with RA are dramatically under evaluated and under treated to reduce the risk…
- Conditions
- Rheumatoid Arthritis, Cardiovascular Diseases, Hyperlipidemias
- Trial name
- CARE RA (NCT04488497)
- Testing
- Cardiovascular Risk Assessment for Patients with Rheumatoid Arthritis, Standard of care
- Where
- United States
- Volunteers
- 101 people, healthy volunteers welcome
- Sponsor
- Weill Medical College of Cornell University
Cardiovascular Disease
Evaluation of Non-invasive Measurements of Atherosclerosis in Cardiovascular Risk Stratification
Multiple risk factors contribute to atherosclerosis, which ultimately results in clinical manifestation of cardiovascular disease.
- Trial name
- NIMA (NCT01555294)
- Where
- Netherlands
- Volunteers
- 1,960 people, healthy volunteers welcome
- Sponsor
- Radboud University Medical Center
Dyslipidemia
Safety and Efficacy of Lapaquistat Acetate Taken Alone and With Atorvastatin in Subjects With Primary Dyslipidemia
The purpose of this study is to evaluate the overall safety of Lapaquistat Acetate, once daily (QD), by itself or in combination with atorvastatin in subjects with primary dyslipidemia.
- Trial name
- NCT00487994
- Testing
- Lapaquistat acetate, Lapaquistat acetate and atorvastatin, Atorvastatin
- Where
- 128 sites in United States, Argentina and 15 more
- Volunteers
- 2,130 people
- Sponsor
- Takeda
Hyperlipidemia
Goal Achievement After Utilizing an Anti-PCSK9 Antibody in Statin Intolerant Subjects-3
The primary objective of this study was to evaluate the effect of 24 weeks of evolocumab administered subcutaneously (SC) every month, compared with ezetimibe, on low-density lipoprotein cholesterol (LDL-C) levels in adults with…
- Trial name
- GAUSS-3 (NCT01984424)
- Testing
- Atorvastatin, Ezetimibe
- Where
- 58 sites in United States, Australia and 11 more
- Volunteers
- 511 people
- Sponsor
- Amgen
HIV, Hyperlipidemia
Coadministration of Ezetimibe With Fenofibrate Versus Pravastatin Monotherapy for the Treatment of Hyperlipidaemia in HIV-infected Patients
The aim of the study is to compare the effects of coadministration of ezetimibe 10 mg/die + fenofibrate 200 mg/die versus pravastatin 40 mg/die monotherapy in HIV-infected patients treated with protease inhibitors.
- Conditions
- HIV, Hyperlipidemia, HIV Infections
- Trial name
- NCT00843661
- Testing
- ezetimibe, fenofibrate, pravastatin
- Where
- Italy
- Volunteers
- 60 people
- Sponsor
- Ospedale di Circolo - Fondazione Macchi
Type II Hyperlipidaemia
Efficacy and Safety of JTT-705 300, 600 And 900mg in Comparison With Placebo in Patients With Type II Hyperlipidaemia
To demonstrate the effect of JTT-705 doses from 300 mg to 900 mg on the elevation of HDL-C and on the inhibition of CETP activity versus placebo, in patients presenting with mild dyslipidaemia.
- Trial name
- NCT00686010
- Testing
- JTT-705 300mg, JTT-705 600mg, JTT-705 900mg
- Where
- Netherlands
- Volunteers
- 198 people
- Sponsor
- Japan Tobacco Inc.